Compare Novavax Inc (NVAX) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Exxon Mobil Corporation — how do they compare? Novavax Inc trades at $12.75 (market cap $1.82B), while Exxon Mobil Corporation trades at $168.94 (market cap $692.86B). The key difference: Exxon Mobil Corporation is far larger — about 380.7× Novavax Inc's market cap, and Exxon Mobil Corporation pays a 2.45% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and Exxon Mobil Corporation for 99 Days on average.
| NVAX | XOM | |
|---|---|---|
Market Cap | $1.82B | $692.86B |
Volume | 6,198,505 | 13,225,996 |
Sector | Health | Energy |
52-Week High | $12.56 | $171.52 |
52-Week Low | $6.22 | $110.64 |
Typical Hold Time | 59 Days | 99 Days |
Enterprise Value | $1.39B | $724.64B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.
Exxon Mobil (XOM) trades at $168.56, up 2.74% today, with a bullish technical signal from moving averages and a consensus analyst price target of $166.67. Recent earnings show mixed results, with a Q2 2026 miss but beats in prior quarters. Revenue has declined from $398.7B in 2022 to $323.9B in 2025, though 2026 projects a rebound to $361.1B. News highlights potential investment in Venezuela's oil fields and expansion in Guyana and the Permian Basin.
XOM presents a stable investment with a 12.55% ROE and dividend yield, but faces risks from volatile oil prices and geopolitical ventures. Analyst sentiment is mixed with 36.36% buy ratings, indicating cautious optimism amid execution risks and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
